OBJECTIVE: Limited evidence is available about the early cardiac manifestation of Fabry disease (FD) in children. We aimed to evaluate cardiac involvement in children with FD by analysing serial structural and electrocardiographic changes. METHODS: The data were acquired from 22 children with FD [11 males; median age 9.8 (ranging 2.5-16) years]. Seven patients (5 males) were on enzyme replacement therapy (ERT) with Agalasidase alpha. Echocardiography, ECG and 24-h ECG monitoring recordings were acquired during routine annual clinical controls. ECG data were compared to a group of age-and gender-matched controls. RESULTS: At baseline, ECG and ECHO parameters of left ventricular mass were similar in both males and females. Three boys (all were on ERT) developed left ventricular hypertrophy (LVH) during two-year follow-up. The progression to LVH was accompanied by the appearance of frequent ventricular premature beats in two cases and supraventricular premature beats (SPBs) with T wave inversion in one case. T wave inversion and SPBs were detected in two younger relatives of a patient with LVH, in the absence of detectable LVH. Seven out of 22 patients had T wave abnormalities. Five of them were males (p = 0.03) all carrying the N215S mutation (p = 0.03). At baseline, median PR intervals were prolonged in FD subjects compared to controls [143 (122-177) vs. 122 (82-165) ms; p < 0.0001]. CONCLUSIONS: Cardiac complications of FD become apparent in childhood as subtle changes with slow but detectable progression over time, with males more frequently affected than females. Progression of LVH was apparent in three children despite ERT.

Department of Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Aryana A, Fifer MA, Ruskin JN, Mela T. Short PR interval in the absence of preexcitation: a characteristic finding in a patient with Fabry disease. Pacing Clin Electrophysiol. 2008;31:782–783. doi: 10.1111/j.1540-8159.2008.01088.x. PubMed DOI

Barbey F, Qanadli SD, Juli C, et al. Aortic remodelling in Fabry disease. Eur Heart J. 2010;31:347–353. doi: 10.1093/eurheartj/ehp426. PubMed DOI

Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA. 2000;248:2771–2775. doi: 10.1001/jama.284.21.2771. PubMed DOI

Cybulla M, Walter K, Neumann HP, et al. Fabry disease: demographic data since introduction of enzyme replacement therapy. Dtsch Med Wochenschr. 2007;132:1505–1509. doi: 10.1055/s-2007-982060. PubMed DOI

Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338–346. doi: 10.7326/0003-4819-138-4-200302180-00014. PubMed DOI

Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458. doi: 10.1016/0002-9149(86)90771-X. PubMed DOI

Dickinson DF. The normal ECG in childhood and adolescence. Heart. 2005;91:1626–1630. doi: 10.1136/hrt.2004.057307. PubMed DOI PMC

Dickinson DF, Scott O. Ambulatory electrocardiographic monitoring in 100 healthy teenage boys. Br Heart J. 1984;51:179–183. doi: 10.1136/hrt.51.2.179. PubMed DOI PMC

Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. J Am Soc Echocardiogr. 2011;24:229–267. doi: 10.1016/j.echo.2010.12.008. PubMed DOI

Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart. 2006;92:357–360. doi: 10.1136/hrt.2004.054015. PubMed DOI PMC

Elliott P, Baker R, Pasquale F, et al. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease Survey. Heart. 2011;97:1957–1960. doi: 10.1136/heartjnl-2011-300364. PubMed DOI

Eng CM, Niehaus DJ, Desnick RJ. Molecular analysis of classical and variant phenotypes. Pediatr Res. 1993;33:128A.

Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am J Hum Genet. 1993;53:1186–1197. PubMed PMC

Frustaci A, Chimenti C. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation. 2007;116:350–351. doi: 10.1161/CIRCULATIONAHA.107.723387. PubMed DOI

Jastrzebski M, Bacior B, Dimitrow PP, Kawecka-Jaszcz K. Electrophysiological study in a patient with Fabry disease and a short PQ interval. Europace. 2006;8:1045–1047. doi: 10.1093/europace/eul121. PubMed DOI

Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40:1668–1674. doi: 10.1016/S0735-1097(02)02380-X. PubMed DOI

Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008;130:367–373. doi: 10.1016/j.ijcard.2008.03.007. PubMed DOI

Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M. Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr. 2008;97:463–469. doi: 10.1111/j.1651-2227.2008.00700.x. PubMed DOI

Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr. 2009;22:709–714. doi: 10.1016/j.echo.2009.03.003. PubMed DOI

Kleinert J, Dehout F, Schwarting A, et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens. 2006;19:782–787. doi: 10.1016/j.amjhyper.2006.01.011. PubMed DOI

Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139:1101–1108. doi: 10.1067/mhj.2000.105105. PubMed DOI

Linhart A, Magage S, Palecek T, Bultas J. Cardiac involvment in Fabry disease. Acta Paediatr Suppl. 2002;91:15–20. doi: 10.1111/j.1651-2227.2002.tb03104.x. PubMed DOI

Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Heart J. 1977;93:699–705. doi: 10.1016/S0002-8703(77)80064-1. PubMed DOI

Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet. 2009;374:1986–1996. doi: 10.1016/S0140-6736(09)61493-8. PubMed DOI

Monserrat L, Gimeno-Blanes JR, Marin F, et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50:2399–2403. doi: 10.1016/j.jacc.2007.06.062. PubMed DOI

Nagueh SF. Fabry disease. Heart. 2003;89:819–820. doi: 10.1136/heart.89.8.819. PubMed DOI PMC

Namdar M, Kampmann C, Steffel J, et al. PQ interval in patients with Fabry disease. Am J Cardiol. 2010;105:753–756. doi: 10.1016/j.amjcard.2009.10.056. PubMed DOI

Namdar M, Steffel J, Vidovic M, et al. Electrocardiographic changes in early recognition of Fabry disease. Heart. 2011;97:485–490. doi: 10.1136/hrt.2010.211789. PubMed DOI

O`Connor M, McDaniel N, Brady W. The pediatric electrocardiogram Part I. Am J Emerg Med. 2008;26:221–228. doi: 10.1016/j.ajem.2007.08.003. PubMed DOI

O'Mahony C, Coats C, Cardona M, et al. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace. 2011;13:1781–1788. doi: 10.1093/europace/eur267. PubMed DOI

Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol. 2011;57:1093–1099. doi: 10.1016/j.jacc.2010.11.018. PubMed DOI

Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabry’s disease with a short PR interval. Am J Cardiol. 1994;74:203–204. doi: 10.1016/0002-9149(94)90106-6. PubMed DOI

Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95:86–92. doi: 10.1080/08035250500275022. PubMed DOI

Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet. 2012;81:485–490. doi: 10.1111/j.1399-0004.2011.01671.x. PubMed DOI

Ries M, Ramaswami U, Parini R, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr. 2003;162:767–772. doi: 10.1007/s00431-003-1299-3. PubMed DOI

Ries M, Clarke JTR, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics. 2006;118:924–932. doi: 10.1542/peds.2005-2895. PubMed DOI

Rijnbeek PR, Witsenburg M, Schrama E, Hess J, Kors JA. New normal limits for the paediatric electrocardiogram. Eur Heart J. 2001;22:702–711. doi: 10.1053/euhj.2000.2399. PubMed DOI

Rijnbeek PR, Herpen G, Kapusta L, Harkel DJ, Witsenburg M, Kors JA. Electrocardiographic criteria for left ventricular hypertrophy in children. Pediatr Cardiol. 2008;29:923–928. doi: 10.1007/s00246-008-9235-y. PubMed DOI PMC

Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407–1411. doi: 10.1161/01.CIR.0000012626.81324.38. PubMed DOI

Scott O, Williams GJ, Fiddler GI. Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years. Br Heart J. 1980;44:304–308. doi: 10.1136/hrt.44.3.304. PubMed DOI PMC

Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005;96:842–846. doi: 10.1016/j.amjcard.2005.05.033. PubMed DOI

Southall DP, Johnston F, Shinebourne EA, Johnston PGB. 24-hour electrocardiographic study of heart rate and rhythm patterns in population of healthy children. Br Heart J. 1981;45:281–291. doi: 10.1136/hrt.45.3.281. PubMed DOI PMC

Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation. 2009;119:2561–2567. doi: 10.1161/CIRCULATIONAHA.108.841494. PubMed DOI

Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51:767–776. doi: 10.1053/j.ajkd.2007.12.032. PubMed DOI

Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005;26:1221–1227. doi: 10.1093/eurheartj/ehi143. PubMed DOI

Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119:524–529. doi: 10.1161/CIRCULATIONAHA.108.794529. PubMed DOI

Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study

Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial